IN2014DN03049A - - Google Patents

Info

Publication number
IN2014DN03049A
IN2014DN03049A IN3049DEN2014A IN2014DN03049A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A IN 3049DEN2014 A IN3049DEN2014 A IN 3049DEN2014A IN 2014DN03049 A IN2014DN03049 A IN 2014DN03049A
Authority
IN
India
Prior art keywords
extracellular matrix
tissue
interstitial
expression
ecm
Prior art date
Application number
Other languages
English (en)
Inventor
Allison A Eddy
Daryl M Okamura
Original Assignee
Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Res Inst filed Critical Seattle Childrens Res Inst
Publication of IN2014DN03049A publication Critical patent/IN2014DN03049A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3049DEN2014 2011-10-26 2011-10-26 IN2014DN03049A (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
IN2014DN03049A true IN2014DN03049A (de) 2015-05-15

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3049DEN2014 IN2014DN03049A (de) 2011-10-26 2011-10-26

Country Status (7)

Country Link
US (2) US9468612B2 (de)
AU (1) AU2011379972B2 (de)
BR (1) BR112014009789A2 (de)
CA (1) CA2853484C (de)
IN (1) IN2014DN03049A (de)
MX (1) MX2014004994A (de)
WO (1) WO2013062544A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028448A2 (pt) * 2015-07-02 2018-08-28 Horizon Orphan Llc análogos de cisteamina resistentes a ado e usos dos mesmos
AU2017235631B2 (en) 2016-03-17 2023-03-02 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3579923A4 (de) * 2017-02-07 2020-11-18 Children's Hospital Medical Center Behandlung von asthma mit cysteamin
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019094862A1 (en) * 2017-11-10 2019-05-16 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
US20220177918A1 (en) * 2019-04-12 2022-06-09 The Regents Of The University Of California Methods for treating inherited eye defects
US12263144B2 (en) 2020-10-13 2025-04-01 Accubit LLC—Biotechnology Methods of treating IgA nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
WO1990000194A1 (en) 1988-06-28 1990-01-11 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (ja) 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
AU639047B2 (en) 1989-11-22 1993-07-15 Genentech Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ES2191007T3 (es) 1991-10-31 2003-09-01 Whitehead Biomedical Inst Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.
EP1230929A1 (de) 1991-11-14 2002-08-14 La Jolla Cancer Research Foundation Inhibitoren von Zellregulationsfaktoren und Verfahren zur Vorbeugung oder Verminderung von Narbenbildung
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
CA2146973C (en) 1992-10-29 2008-09-02 Patricia R. Segarini Uses of tgf-.beta. receptor fragment as a therapeutic agent
WO1994010187A1 (en) 1992-10-30 1994-05-11 Hsc Research And Development Limited Partnership COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
WO1994025588A2 (en) 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
EP0737071A1 (de) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense-oligodeoxynukleotide zu fibrogenen cytokinen und ihre verwendung
WO1995010610A1 (en) 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
US5981483A (en) 1994-05-04 1999-11-09 Mount Sinai Hospital Corporation Compositions comprising modulators of cytokines of the TGF-β superfamily
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU2749697A (en) 1996-04-30 1997-11-19 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
AU740052B2 (en) 1996-10-25 2001-10-25 Ethicon Inc. Anti-fibrotic agent assay
WO1998048024A1 (en) 1997-04-18 1998-10-29 Biogen, Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002066462A1 (en) 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
EP1363904A1 (de) 2001-02-02 2003-11-26 Glaxo Group Limited Pyrazole als tgf-inhibitoren
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005530800A (ja) 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
BR0314196A (pt) 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
EP1543001B1 (de) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
US20060079680A1 (en) 2002-11-22 2006-04-13 Eli Lilly And Company Patent Division Pyrazoloazepine compounds as pharmaceutical agents
US20040127575A1 (en) 2002-11-22 2004-07-01 Feng Ying Method for counteracting a pathologic change in the beta-adrenergic pathway
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
AU2003291149A1 (en) 2002-11-22 2004-06-18 Scios, Inc. USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
EP1567527A1 (de) 2002-11-27 2005-08-31 Eli Lilly And Company Kondensierte pyrazolderivate
WO2004056352A1 (en) 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7223766B2 (en) 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
EP1646655A2 (de) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 liganden
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1708712A1 (de) 2003-12-24 2006-10-11 Scios, Inc. Behandlung von malignen gliomen mit tgf-beta-hemmern
EP1723146A1 (de) 2004-03-01 2006-11-22 Eli Lilly And Company Kondensierte pyrazolderivate als inhibitoren der tgf-beta-signalvermittlung zur behandlung von fibrose und neoplasmen
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
EP1786803A1 (de) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazole als tgf-beta-inhibitoren
EP1786802A1 (de) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylimidazole als tgf-beta-hemmer
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
ES2388310T7 (es) 2006-01-27 2017-05-03 The Regents Of The University Of California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
WO2008070117A1 (en) 2006-12-04 2008-06-12 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
KR20100091219A (ko) * 2007-11-30 2010-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 시스테아민 산물을 이용한 비-알코올성 지방성간염(ｎａｓｈ) 치료 방법

Also Published As

Publication number Publication date
MX2014004994A (es) 2014-08-27
AU2011379972A1 (en) 2014-05-15
BR112014009789A2 (pt) 2017-04-25
US9925154B2 (en) 2018-03-27
WO2013062544A1 (en) 2013-05-02
US9468612B2 (en) 2016-10-18
CA2853484A1 (en) 2013-05-02
AU2011379972B2 (en) 2016-05-12
CA2853484C (en) 2018-08-21
US20170165207A1 (en) 2017-06-15
US20140275279A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IN2014DN03049A (de)
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
IL226127A0 (en) A compound containing hydrolyzed proteins and an oligosaccharide for the treatment of skin diseases
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
BR112013029800A2 (pt) tratamento de degeneração do disco intervertebral com o uso de células derivadas do tecido do tecido do cordão umbilical humano
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
PT3087178T (pt) Método para produzir oxalato oxidases que têm atividade ótica próxima ao ph fisiológico e utilização de tais oxalato oxidases recombinantes no tratamento de doenças relacionadas com oxalato
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
HUE054196T2 (hu) Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
HRP20150117T1 (xx) Pripravci kolagenaze g i kolagenaze h za lijeäśenje bolesti koje ukljuäśuju promjene kolagena
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
ZA201302638B (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
NZ595440A (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
WO2011038417A9 (en) Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation
IL215406A0 (en) Electromedical device for the non-invasive reduction or removal of subcutaneous adipose tissue
GB201018154D0 (en) Method of treatment
AU336535S (en) Medical dressing
AU336536S (en) Medical dressing
ZA201005770B (en) The treatment of damaged skin
UA44660U (ru) Способ лечения больных системными заболеваниями соединительной ткани с преимущественным поражением кожи
AU2010905197A0 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
UA99774C2 (ru) Лечение воспалительных заболеваний бета-дефензинами млекопитающих
UA65158U (ru) Способ лечения трофических язв нижних конечностей